@article{2c168c0c8d21438a98d53d294579ae71,
title = "Increased expression of Kalirin-9 in the auditory cortex of schizophrenia subjects: Its role in dendritic pathology",
abstract = "Reductions in dendritic arbor length and complexity are among the most consistently replicated changes in neuronal structure in post mortem studies of cerebral cortical samples from subjects with schizophrenia, however, the underlying molecular mechanisms have not been identified. This study is the first to identify an alteration in a regulatory protein which is known to promote both dendritic length and arborization in developing neurons, Kalirin-9. We found Kalirin-9 expression to be paradoxically increased in schizophrenia. We followed up this observation by overexpressing Kalirin-9 in mature primary neuronal cultures, causing reduced dendritic length and complexity. Kalirin-9 overexpression represents a potential mechanism for dendritic changes seen in schizophrenia.",
keywords = "Auditory cortex, Dendrite, Endophenotypes, Kalirin, Schizoaffective, Schizophrenia",
author = "Deo, {Anthony J.} and Cahill, {Michael E.} and Siyu Li and Isaac Goldszer and Ruth Henteleff and VanLeeuwen, {Jon Eric} and Igor Rafalovich and Ruoqi Gao and Stachowski, {Erin K.} and Sampson, {Allan R.} and Lewis, {David A.} and Peter Penzes and Sweet, {Robert A.}",
note = "Funding Information: This work was supported by the NIH grants MH071533, MH084053 and MH071316 . Anthony Deo was supported by a Clinical Research Fellow grant from the Doris Duke Charitable Foundation to the University of Pittsburgh School of Medicine. Michael Cahill is supported by NIH F31AG031621-01A2 ; Jon VanLeeuwen is supported by NIH 1F31MH087043 . Allan R. Sampson is a statistical consultant to Johnson & Johnson Pharmaceutical Research and Development. Dr. Lewis currently receives investigator-initiated research support from the BMS Foundation , Bristol-Myers Squibb , Curridium Ltd and Pfizer and in 2007–2010 served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science. The authors thank Josephine Asafu-Adjei for statistical assistance. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs or the United States Government.",
year = "2012",
month = feb,
doi = "10.1016/j.nbd.2011.11.003",
language = "English (US)",
volume = "45",
pages = "796--803",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "2",
}